Citations

Clear

9383 citation(s) found for "Thomas, PS".

Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Vinayak, Shaveta , Sun, Tianyi , Kuderer, Nicole M. , Balmaceda, Nicole , Bilen, Mehmet Asım , Bindal, Poorva , Blau, Sibel , Bodin, Brianne E, Borno, Hala T. , Choi, Horyun, Deeken, John F. , Edwin, Natasha, Feldman, Lawrence , Flora, Daniel , Galsky, Matthew D. , Gonzalez, Cyndi J, Grivas, Petros , Gupta, Shilpa , Haynam, Marcy , Heilman, Hannah, Jhawar, Sachin R, Kaklamani, Virginia , Klein, Elizabeth J. , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Lammers, Philip E. , Lathrop, Kate, Lewis, Mark A. , Lopes, Gilbert de Lima, Makower, Della , Mansoor, Abdul-Hai, Mashru, Sandeep H., McKay, Rana R. , Messing, Ian , Mico, Vasil, Nadkarni, Rajani, Namburi, Swathi, Nguyen, Ryan H, Nonato, Taylor K., Park, Kyu, Patel, Jaymin , Patel, Kanishka G. , Peppercorn, Jeffrey , Polimera, Hyma , Puc, Matthew , Reid, Sonya , Riess, Jonathan W. , Rivera, Donna R. , Russ, Atlantis Dawn, Schapira, Lidia , Shanahan, M Kelly, Smits, Melissa, Streckfuss, Mitrianna, Thompson, Michael A, Tolaney, Sara M. , Weissmann, Lisa B., Wilson, Grace, Wulff‐Burchfield, Elizabeth , French, Benjamin , Accordino, Melissa , Nagaraj, Gayathri , Khaki, Ali Raza , Aboulafia, David M. , Acoba, Jared David , Awosika, Joy A. , Bakouny, Ziad , Bao, Ting , Bashir, Babar , Berg, Stephanie , Castellano, Cecilia A. , Desai, Aakash , Friese, Christopher R. , Hershman, Dawn L. , Hwang, Clara , Jani, Chinmay , Jhawar, Sachin R, Joshi, Monika , Knox, Natalie, Labaki, Chris , Li, Xuanyi , Lyman, Gary H , Markham, Merry Jennifer , Nguyen, Ryan H, O’Connor, Tracey L. , Panagiotou, Orestis A. , Rao, Yuan James , Razavi, Pedram , Robson, Mark E. , Rose, Suzanne J. , Shah, Pankil , Shapiro, Lauren C. , Stover, Daniel G. , Tachiki, Lisa , Thompson, Michael A, Wotman, Michael T. , Mishra, Sanjay , Warner, Jeremy L. , Lustberg, Maryam B. , Shah, Dimpy P.

Mayo Clinic

No container title available | November 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.82618.sa2 Get It

Identifying the white matter pathways involved in multiple sclerosis-related tremor using diffusion tensor imaging
Bayoumi, Ahmed , Hasan, Khader M. , Patiño, Jorge , Thomas, Joseph, Gabr, Refaat E. , Pedroza, Claudia , Schiess, Mya C. , Wolinsky, Jerry S. , Lincoln, John A. , Gabr, Refaat E , Wolinsky, Jerry S , Lincoln, John A , Keser, Zafer , Keser, Zafer , Kamali, Arash

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | November 8, 2023 | Volume: 9 | Issue: 4 | Pages: No page available

10.1177/20552173231208271 | PMID 38021452 Get It

Background Tremor affects up to 45% of patients with Multiple Sclerosis (PwMS). Current understanding is based on insights from other neurological disorders, thus, not fully addressing the distinctive aspects of MS pathology. Objective To characterize the brain white matter (WM) correlates of MS-related tremor using diffusion tensor imaging (DTI). Methods In a prospective case-control study, PwMS with tremor were assessed for tremor severity and underwent MRI scans including DTI. PwMS without tremor served as matched controls. After tract selection and segmentation, the resulting diffusivity measures were used to calculate group differences and correlations with tremor severity. Results This study included 72 PwMS. The tremor group (n = 36) exhibited significant changes in several pathways, notably in the right inferior longitudinal fasciculus (Cohen's d = 1.53, q < 0.001) and left corticospinal tract ( d = 1.32, q < 0.001), compared to controls (n = 36). Furthermore, specific tracts showed a significant correlation with tremor severity, notably in the left medial lemniscus (Spearman's coefficient [ rsp] = −0.56, p < 0.001), and forceps minor of corpus callosum ( rsp = -0.45, p < 0.01). Conclusion MS-related tremor is associated with widespread diffusivity changes in WM pathways and its severity correlates with commissural and sensory projection pathways, which suggests a role for proprioception or involvement of the dentato-rubro-olivary circuit.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Advani, Ranjana H. , Andreadis, B., Chang, Julie , Christian, Beth , deVos, Sven, Fayad, Luis , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Karimi, Yasmin , King, Rebecca L. , Krivacic, Susan, LaCasce, Ann S. , Messmer, Marcus , Narkhede, Mayur , Rabinovitch, Rachel , Roberts, Kenneth B. , Smith, Stephen D. , Svoboda, Jakub , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Advani, Ranjana H , Karimi, Yasmin H , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Bartlett, Nancy L. , Budde, Lihua E. , Caimi, Paolo F. , Dholaria, Bhagirathbhai , Habermann, Thomas M. , Hu, Boyu , Kelsey, Chris R. , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2023 | Volume: 21 | Issue: 11 | Pages: 1118-1131

10.6004/jnccn.2023.0057 | PMID 37935098 Get It

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Schmults, Chrysalyne D. , Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad , Amini, Arya , Bibee, Kristin , Chen, Pei-Ling , DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , Lukens, John N. , Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Patel, Tejesh , Rich, Jason T. , Sekulić, Aleksandar , Shaha, Ashok R. , Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Alam, Murad , Bordeaux, Jeremy S. , Contreras, Carlo M. , Donigan, Jessica M. , Ho, Alan L. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Puzanov, Igor , Srivastava, Divya , Tomblinson, Courtney, Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2023 | Volume: 21 | Issue: 11 | Pages: 1181-1203

10.6004/jnccn.2023.0056 | PMID 37935106 Get It

Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise. Exposure to radiation, from either sunlight or previous medical therapy, is a key player in BCC development. BCC is not as aggressive as other skin cancers because it is less likely to metastasize. However, surgery and radiation are prevalent treatment options, therefore disfigurement and limitation of function are significant considerations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline an updated risk stratification and treatment options available for BCC.
Biomarkers of Cellular Senescence Predict the Onset of Mobility Disability and Are Reduced by Physical Activity in Older Adults
Fielding, Roger A. , Atkinson, Elizabeth J. , Aversa, Zaira, White, Thomas A. , Heeren, Amanda A., Mielke, Michelle M. , Cummings, Steven R. , Pahor, Marco, Mielke, Michelle M , Leeuwenburgh, Christiaan , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology: Series A | November 7, 2023 | Volume: 79 | Issue: 3 | Pages: No page available

10.1093/gerona/glad257 | PMID 37948612 Get It

Abstract Studies in mice and cross-sectional studies in humans support the premise that cellular senescence is a contributing mechanism to age-associated deficits in physical function. We tested the hypotheses that circulating proteins secreted by senescent cells are (i) associated with the incidence of major mobility disability (MMD), the development of persistent mobility disability (PMMD), and decrements in physical functioning in older adults, and (ii) influenced by physical activity (PA). Using samples and data obtained longitudinally from the Lifestyle Interventions in Elders Study clinical trial, we measured a panel of 27 proteins secreted by senescent cells. Among 1 377 women and men randomized to either a structured PA intervention or a healthy aging (HA) intervention, we observed significant associations between several senescence biomarkers, most distinctly vascular endothelial growth factor A (VEGFA), tumor necrosis factor receptor 1 (TNFR1), and matrix metallopeptidase 7 (MMP7), and the onset of both MMD and PMMD. Moreover, VEGFA, GDF15, osteopontin, and other senescence biomarkers were associated with reductions in short physical performance battery scores. The change in senescence biomarkers did not differ between PA and HA participants. In the whole cohort, higher levels of PA were associated with significantly greater reductions in 10 senescence-related proteins at 12 and/or 24 months. These data reinforce cellular senescence as a contributing mechanism of age-associated functional decline and the potential for PA to attenuate this hallmark of aging. Clinical Trials Registration Number: NCT01072500
Abstract 13886: Impaired Locomotor Muscle Blood Flow During Cycling Exercise in Heart Failure With Preserved Ejection Fraction
Cifci, Gizem , Bruhn, Eric J., Olson, Thomas P. , Hammer, Shane M. , Bissen, Thomas G. , Borlaug, Barry A. , Smith, Joshua R.

Mayo Clinic

Circulation | November 6, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.13886 Get It

Introduction: Obesity and hypertension (HTN) are highly prevalent comorbid risk factors for heart failure with preserved ejection fraction (HFpEF). Obesity and HTN independently increase sympathetic nervous activity and impair muscle blood flow during exercise. Previous work has reported attenuated limb blood flow in patients with HFpEF; however, these findings were compared to controls with dissimilar comorbidities and during small muscle mass exercise. It is unclear if HFpEF alters muscle blood flow responses independent of the obesity- and HTN-mediated alterations. Hypothesis: We hypothesized the muscle blood flow response during cycling would be lower in HFpEF patients than age, sex, BMI, and HTN matched controls (CTL). Methods: HFpEF patients (n=14, 9M/5W, 71±7yrs, 32±4 kg/m 2 ) and CTL (n=12, 8M/4W, 69±7yrs, 31±4 kg/m 2 ) performed an incremental cycling test. Blood pressure was measured by manual sphygmomanometry, cardiac output (Q) by open-circuit acetylene wash-in technique, and systemic vascular resistance (SVR) was calculated. Vastus lateralis blood flow index (BFI) was measured by near-infrared spectroscopy and indocyanine green dye injections and venous norepinephrine concentration was measured. Changes from rest to 40 W of the incremental test are reported. Results: Resting Q, mean arterial pressure, SVR, and venous norepinephrine concentration were not statistically different between groups (p>0.18). From rest to 40 W, the increases in Q (CTL: 3.9±0.8 vs. HFpEF: 3.6±0.7 L/min), mean arterial pressure (CTL: 5.7±2.7 vs. HFpEF: 6.6±6.1 mmHg), and SVR (CTL: -7.3±2.1 vs. HFpEF: -6.0±2.0 mmHg/L/min) were not statistically different between groups (all, p>0.13). The HFpEF group had smaller increases in vastus lateralis BFI at 40 W compared to CTL (CTL: 7.2±3.6 vs. HFpEF: 4.2±2.6 fold-increase from rest) (p=0.02). The HFpEF group had greater increases in venous norepinephrine concentration from rest to 40 W than CTL (CTL: 164±216 vs. HFpEF: 377±247 pg/mL) (p=0.05). Conclusions: Our findings suggest that, compared to age, sex, BMI, and HTN matched controls, patients with HFpEF have an impaired locomotor muscle blood flow response during submaximal cycling exercise likely due to higher locomotor muscle vascular resistance.
Development and validation of a model to predict acute kidney injury following high‐dose methotrexate in patients with lymphoma
Rice, Mikhaila , Frazee, Erin N. , Rule, Andrew D. , Martin, Catherine E. , Truong, Huong L. , Mara, Kristin C. , Kashani, Kianoush , Thompson, Carrie A. , Witzig, Thomas E. , Barreto, Jason N. , Witzig, T.E. , Rice, Mikhaila L , Frazee, Erin N , Kashani, Kianoush B , DeFino, Catherine E. , Rule, Andrew D , Mara, Kristin C

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | November 5, 2023 | Volume: 44 | Issue: 1 | Pages: 4-12

10.1002/phar.2889 | PMID 37926860 Get It

AbstractStudy ObjectiveTo develop and validate a model for predicting acute kidney injury (AKI) after high‐dose methotrexate (HDMTX) exposure.DesignRetrospective analysis.SettingMultisite integrated health system throughout Minnesota and Wisconsin.PatientsAdult patients with lymphoma who received HDMTX as a 4‐h infusion.Measurements and Main ResultsLASSO methodology was used to identify factors available at the outset of therapy that predicted incident AKI within 7 days following HDMTX. The model was then validated in an independent cohort. The incidence of AKI within 7 days following HDMTX was 21.6% (95% confidence interval (CI) 18.4%‐24.8%) in the derivation cohort (435 unique patients who received a total of 1642 doses of HDMTX) and 15.6% (95% CI 5.3%‐24.8%) in the validation cohort (55 unique patients who received a total of 247 doses of HDMTX). Factors significantly associated with AKI after HDMTX in the multivariable model included age ≥ 55 years, male sex, and lower HDMTX dose number. Other factors that were not found to be significantly associated with AKI on multivariable analysis, but were included in the final model, were body surface area, Charlson Comorbidity Index, and estimated glomerular filtration rate. The c‐statistic of the model was 0.72 (95% CI 0.69‐0.75) in the derivation cohort and 0.72 (95% CI 0.60‐0.84) in the validation cohort.ConclusionThis model utilizing identified sociodemographic and clinical factors is predictive of AKI following HDMTX administration in adult patients with lymphoma.
Comparative Effectiveness of Secondary Furlow and Buccal Myomucosal Flap Lengthening to Treat Velopharyngeal Insufficiency
Snodgrass, Taylor D. , Temkit, M’hamed , Singh, Davinder , Singh, Davinder J , Snodgrass, Taylor , Sitzman, Thomas J. , Perry, Jamie L. , Chee-Williams, Jessica L.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | November 3, 2023 | Volume: 11 | Issue: 11 | Pages: e5375

10.1097/gox.0000000000005375 | PMID 37928635 Get It

Background: Secondary Furlow (Furlow) and buccal myomucosal flaps (BMMF) treat velopharyngeal insufficiency by lengthening the palate and retropositioning the levator veli palatini muscles. The criteria for choosing one operation over the other remain unclear. Methods: A single-center retrospective cohort study was conducted. Thirty-two patients with nonsyndromic, repaired cleft palate were included. All patients underwent a Furlow or BMMF. Outcome measures included (1) resolution of hypernasality 12 months postoperatively, (2) degree of improvement of hypernasality severity; and (3) change in velar length, as measured on magnetic resonance imaging scans obtained preoperatively and 12 months postoperatively. All measures were performed by raters blinded to participants’ medical and surgical history. Results: Hypernasality was corrected to normal in 80% of the Furlow group and in 56% of the BMMF group. Patients receiving BMMF had more severe hypernasality during preoperative speech evaluation. Both groups had a median decrease of two scalar rating points for severity of hypernasality (P = 0.58). On postoperative magnetic resonance imaging, patients who underwent Furlow had a median increased velar length of 6.9 mm. Patients who received BMMF had a median increased velar length of 7.5 mm. There was no statistically significant difference between groups regarding increase in velar length (P = 0.95). Conclusions: Furlow and BMMF procedures increase velar length with favorable speech outcomes. The same degree of improvement for hypernasality was observed across groups, likely explained by the similar increase in velar length achieved. Anatomic changes in palate length and levator veli palatini retropositioning persist 1 year after surgery.
Functional and anatomical connectivity predict brain stimulation’s mnemonic effects
Ezzyat, Youssef , Aronson, Joshua P. , Jobst, Barbara C. , Sheth, Sameer A. , Wanda, Paul A., Rizzuto, Daniel S. , Kahana, Michael J. , Jobst, Barbara , Kragel, James E. , Solomon, Ethan A. , Lega, Bradley Charles , Gross, Robert E. , Sperling, Michael R. , Worrell, Gregory A.

Mayo Clinic

Cerebral Cortex | November 2, 2023 | Volume: 34 | Issue: 1 | Pages: No page available

10.1093/cercor/bhad427 | PMID 38041253 Get It

Abstract Closed-loop direct brain stimulation is a promising tool for modulating neural activity and behavior. However, it remains unclear how to optimally target stimulation to modulate brain activity in particular brain networks that underlie particular cognitive functions. Here, we test the hypothesis that stimulation’s behavioral and physiological effects depend on the stimulation target’s anatomical and functional network properties. We delivered closed-loop stimulation as 47 neurosurgical patients studied and recalled word lists. Multivariate classifiers, trained to predict momentary lapses in memory function, triggered the stimulation of the lateral temporal cortex (LTC) during the study phase of the task. We found that LTC stimulation specifically improved memory when delivered to targets near white matter pathways. Memory improvement was largest for targets near white matter that also showed high functional connectivity to the brain’s memory network. These targets also reduced low-frequency activity in this network, an established marker of successful memory encoding. These data reveal how anatomical and functional networks mediate stimulation’s behavioral and physiological effects, provide further evidence that closed-loop LTC stimulation can improve episodic memory, and suggest a method for optimizing neuromodulation through improved stimulation targeting.
754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
Chumsri, Saranya , Migdady, Yazan , Chaudhary, Lubna N. , Kim, Chul , Fitzsimmons, Sarah, Ganguly, Bishwa J, Hiraragi, Hajime, Jensen, H.R., Kim, Yeonhee , Lessig, Mary, Gillenwater, Heidi H., Spigel, David R. , Hamilton, Erika , Bashir, Babar , Gergis, Usama , Murthy, Hemant S. , Specht, Jennifer M. , Garber, Haven R. , Mamdani, Hirva Mansurali , Jensen, Helle

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A850-A850

10.1136/jitc-2023-sitc2023.0754 Get It